Streetbeat News

Revenues

APPN

In the last three months, 5 analysts have updated their ratings on Appian (NASDAQ:APPN), showing a mix of views from bullish to bearish. The average 12-month price target is now $47.0, up from $46.60, with actions including both raises and lowers in ratings and price targets by firms like Barclays, Citigroup, DA Davidson, and Keybanc. Appian's financials show a revenue growth of 15.53% but lag behind industry peers, with challenges in profitability, asset utilization, and high debt levels.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 1:01 pm

ROL

Four analysts have recently updated their ratings on Rollins (NYSE:ROL), showing a mix of bullish and indifferent sentiments. The average 12-month price target is now $50.5, reflecting a slight increase from the previous target. Rollins, a global leader in pest-control services, has demonstrated strong financial performance with a 14.02% revenue growth rate, impressive net margin, and exceptional ROE and ROA. The company's debt management is also noted positively, with a debt-to-equity ratio below industry average.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 1:00 pm

SGML

Sigma Lithium Corporation (SGML) has begun loading its 8th shipment of 22,000 tonnes of high-purity lithium concentrate, achieving a premium fixed price of $1,333/t, equivalent to $1,160/t net of VAT. This price represents a significant increase over previous prices and is 8.75% of the LME Lithium Hydroxide CIF market price. 85% of the shipment's value has been prepaid, indicating strong market demand and confidence in Sigma Lithium's product. The company plans to continue optimizing its commercial strategy for future production.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:46 pm

SPY

U.S. retail sales for March increased by 0.7%, surpassing the estimated 0.4% and the previous month's 0.9%.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:30 pm

SPY

XRT

US Core Retail Sales for March increased by 1.1%, surpassing the estimated 0.5%. This indicates a stronger consumer spending than anticipated.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:30 pm

URGN

UroGen Pharma Ltd. (NASDAQ:URGN) announced FDA acceptance of its IND application for UGN-103, a novel mitomycin-based formulation for treating low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen plans to initiate a Phase 3 study in 2024, with potential advantages including a new 80 mg dosage strength, simplified manufacturing, and extended intellectual property protection until December 2041. UGN-103 utilizes UroGen's RTGel platform technology. Additionally, UroGen is preparing for an NDA submission for UGN-102, another mitomycin formulation, in September 2024.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:11 pm

HYMTF

Kia, a subsidiary of Hyundai Motor (OTC:HYMTF), has launched a cash incentive program for U.S. dealers to clear inventory of 2023 EV models and make room for 2024 models. The 'Kia April 2024 Dealer Flat Cash Program' offers $1,000 for each 2023 EV6 sold, $1,500 for the EV6 GT, and smaller incentives for 2024 models. Despite a slight drop in total vehicle sales, Kia's EV sales in the U.S. have significantly increased, with a notable jump in EV9 and EV6 sales.

Portfolio Pulse from Anan Ashraf

April 15, 2024 | 12:08 pm

SCHW

Schwab reported March core net new assets totaling $45 billion, with total client assets reaching $9.1 trillion, marking a 20% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:03 pm

CLSK

Cleanspark (NASDAQ:CLSK), a bitcoin mining company, has received diverse analyst ratings over the last three months, with a trend towards bullish evaluations. The average 12-month price target for CLSK is now $22.4, reflecting a significant increase from the previous average of $14.86. This upward revision is supported by Cleanspark's strong financial performance, including a revenue growth rate of 170.26%, a net margin of 34.33%, and an ROE of 3.41%. The company's market capitalization and financial metrics indicate a robust position in the industry, with a debt-to-equity ratio well below the industry average.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 12:01 pm

BC

Brunswick (NYSE:BC) has received mixed analyst ratings over the past three months, with a total of 7 analysts offering their views. The recent ratings show a shift towards a more cautious stance, with one indifferent rating in the last 30 days compared to two bullish and one indifferent rating two months ago. Analysts have updated their 12-month price targets for Brunswick, setting an average target of $96.86, which is an increase from the previous $93.43. The company has faced a revenue decline of -13.95% as of December 31, 2023, but maintains a strong net margin of 4.47% and an exceptional return on equity (ROE) of 2.92%, despite challenges in debt management.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 12:01 pm